Kuros Biosciences AG (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
43
About the Report
About the Report
Summary
Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company's lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.
Kuros Biosciences AG (KURN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Kuros Biosciences AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Kuros Biosurgery Raises Additional USD5 Million Financing 12
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13
Merger 14
Cytos Biotech Merges with Kuros Biosurgery 14
Licensing Agreements 15
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Equity Offering 18
Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Kuros Biosciences Raises Funds through Public Offering of Shares 20
Cytos Biotechnology Completes Rights Offering Of Shares For USD 26.7 Million 21
Cytos Biotechnology Completes Private Placement Of Shares For USD 26 Million 22
Cytos Biotechnology Completes Rights Offering Of Shares For USD 3.5 Million 24
Debt Offering 26
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For USD 14.5 Million 26
Kuros Biosciences AG-Key Competitors 28
Kuros Biosciences AG-Key Employees 29
Kuros Biosciences AG-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 05, 2018: Kuros Biosciences announces results for first half 2018 31
Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results 32
Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 33
Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 34
Corporate Communications 36
Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer 36
May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM 37
Dec 14, 2017: Kuros Biosciences Announces Management Succession 38
Nov 28, 2017: Kuros Biosciences' Chief Medical Officer to Retire 39
Nov 16, 2017: Kuros announces management changes 40
Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 41
Apr 13, 2017: Kuros announces CEO succession 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Figure
List of Figures
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kuros Biosurgery Raises Additional USD5 Million Financing 12
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13
Cytos Biotech Merges with Kuros Biosurgery 14
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Kuros Biosciences Raises Funds through Public Offering of Shares 20
Cytos Biotechnology Completes Rights Offering Of Shares For USD 26.7 Million 21
Cytos Biotechnology Completes Private Placement Of Shares For USD 26 Million 22
Cytos Biotechnology Completes Rights Offering Of Shares For USD 3.5 Million 24
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For USD 14.5 Million 26
Kuros Biosciences AG, Key Competitors 28
Kuros Biosciences AG, Key Employees 29
Kuros Biosciences AG, Subsidiaries 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.